Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Sepiapterin: First Approval.

Drugs·2025
Same author

Tiratricol: First Approval.

Drugs·2025
Same author

Tasurgratinib Succinate: First Approval.

Drugs·2025
Same author

Correction: Fulzerasib: First Approval.

Drugs·2025
Same author

Marstacimab: First Approval.

Drugs·2024
Same author

Correction: Vorasidenib: First Approval.

Drugs·2024
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Sep 18, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

雷卡西马布:首次获得批准

Yvette N Lamb1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|June 22, 2025
PubMed
概括
此摘要是机器生成的。

针对PCSK9的新型抗体雷卡西马布在中国首次获得批准,用于治疗高胆固醇血症和混合性脂质失调症. 这标志着降脂疗法在不对他类药物有反应的患者中取得了重大进展.

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

相关实验视频

Last Updated: Sep 18, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

科学领域:

  • 心血管药理学心血管药理学
  • 免疫学 免疫学 免疫学
  • 药物开发 药物开发

背景情况:

  • 高胆固醇血症和混合性失脂血症是心血管疾病的重要危险因素.
  • 目前的降脂疗法,包括他类药物,并不能在所有患者中达到目标低密度脂蛋白胆固醇 (LDL-C) 水平.
  • 蛋白转化酶亚素/素9型 (PCSK9) 是LDL-C代谢的关键调节者.

研究的目的:

  • 总结一下recaticimab的发展里程碑,这是一种针对PCSK9.9的人性化单克隆抗体.
  • 为了突出雷卡西马布在高胆固醇血症和混合性脂质失调症的监管批准.

主要方法:

  • 雷卡西马布是一种人性化的单克隆免疫球蛋白G1抗体.
  • 它向PCSK9,抑制其与LDL受体的相互作用.
  • 开发涉及临床前和临床研究 (细节未提供摘要).

主要成果:

  • 雷卡西马布于2025年1月8日在中国获得首次批准.
  • 在未达到LDL-C目标的成年人中被批准作为初级高胆固醇血症和混合性脂质失调症的饮食和他类药物的辅助剂.
  • 已被批准作为非家族性高胆固醇血症和混合性脂质失调症的单疗法,以降低LDL-C,总胆固醇和阿波利波蛋白B.

结论:

  • 雷卡西马布代表了治疗高胆固醇血症和混合性脂质失调症的新疗法.
  • 批准标志着PCSK9抑制剂开发的里程碑.
  • 这一进步为需要额外的降脂治疗的患者提供了新的策略.